ChAdOx1 nCoV-19 prime cohort
comorbidity
A total of 190 participants were enrolled and 187 were randomized. Of these, 186 received the study vaccine (92 SII-NVX-CoV2373 and 94 ChAdOx1 nCoV-19). Only a single participant withdrew the consent before day 29. The safety population comprised 186 participants, both full analysis and per protocol populations comprised 185 participants (Fig. CONSORT flow chartThe demographic and baseline characteristics between the groups were comparable. Mean age was about 36 years and 45% were males. About 15% participants had comorbidity. None of the participants was SARS CoV-2 RT-PCR positive. Median duration between two doses of prime series of ChAdOx1 nCoV-19 was 90 days and that between second dose of prime series and the booster dose was 270 days. The proportion of participants with seropositivity for anti-S IgG or nAbs at baseline was comparable between the groups (Table Demographics and baseline characteristics - safety population.